Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Product royalty revenues	$ 1,082,742	$ 2,716,452	$ 1,884,080
Research revenue	13,375	227,668	726,948
Sponsored research revenue			244,479
Contract revenue	53,446,309	318,800	549,390
Total revenues	54,542,426	3,262,920	3,404,897
Cost of product royalties	1,909,785	1,756,629	839,208
Expenses:
Research and development	35,365,662	20,805,177	10,645,414
General and administrative	10,114,689	7,608,090	7,913,370
Related party general and administrative	90,500	81,000	82,529
Impairment of intangible license			243,648
Total expenses	45,570,851	28,494,267	18,884,961
Income (Loss) from operations	7,061,790	(26,987,976)	(16,319,272)
Interest income (expense), net	280,709	188,701	133,613
Derivative (loss) gain	(5,594,152)	3,463,453	3,126,771
Other income (expenses), net	32,954	10,706	25,946
Total nonoperating Income (Expense)	(5,280,489)	3,662,860	3,286,330
Income (Loss) before taxes	1,781,301	(23,325,116)	(13,032,942)
Income tax expense	(129,120)
Net income (loss)	1,652,181	(23,325,116)	(13,032,942)
Net income (loss) attributable to common stockholders	$ 1,652,181	$ (23,325,116)	$ (13,032,942)
Basic:
Weighted average common stock shares outstanding	30,546,581	28,322,477	23,150,975
Basic earnings per share	$ 0.05	$ (0.82)	$ (0.56)
Diluted:
Diluted weighted average common stock shares outstanding	30,689,235	28,322,477	23,150,975
Diluted earnings per share	$ 0.05	$ (0.82)	$ (0.56)